デフォルト表紙
市場調査レポート
商品コード
1463911

経口ドラッグデリバリー市場- 世界の産業規模、シェア、動向、機会、予測、製剤別、タイプ別、治療領域別、エンドユーザー別、地域別、競合別、2019年~2029年

Oral Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Formulation, By Type, By Therapy Area, By End User, By Region and Competition, 2019-2029F

出版日: | 発行: TechSci Research | ページ情報: 英文 185 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

経口ドラッグデリバリー市場- 世界の産業規模、シェア、動向、機会、予測、製剤別、タイプ別、治療領域別、エンドユーザー別、地域別、競合別、2019年~2029年
出版日: 2024年04月15日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

経口ドラッグデリバリーの世界市場規模は2023年に1,204億4,000万米ドルとなり、2029年までのCAGRは7.74%で、予測期間中に目覚ましい成長を遂げると予測されています。

経口ドラッグデリバリー市場は、経口経路で投与される薬剤の開発、製造、商品化を専門とする製薬業界のセクターを包含します。経口ドラッグデリバリーは、その利便性、使いやすさ、患者のコンプライアンスから、薬物投与において最も一般的で好まれる方法の1つであるため、この市場セグメントは非常に重要です。経口ドラッグデリバリーシステムには、錠剤、カプセル剤、液剤、口腔内崩壊錠など、幅広い製剤が含まれます。この市場において、製薬会社は、薬効、バイオアベイラビリティ、患者の転帰を高めることを目的とした新しいドラッグデリバリー技術を革新するため、研究開発に多額の投資を行っています。

主な市場促進要因

慢性疾患の有病率の上昇

ドラッグデリバリープラットフォームの技術革新

製薬業界の投資拡大

ヘルスケアアクセス向上のための政府の取り組み

主な市場課題

バイオアベイラビリティの向上

規制遵守と知的財産保護

主要市場動向

個別化医療とオーダーメイド製剤

デジタルヘルス技術の統合

セグメント別の洞察

製剤別の洞察

タイプ別の洞察

地域別の洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の経口ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 剤形別(錠剤、カプセル剤、ドロップ剤、液剤、シロップ剤)
    • タイプ別(放出制御錠、口腔内分散錠、その他)
    • 治療領域別(腫瘍、筋骨格系、免疫、消化器、呼吸器、循環器、その他)
    • エンドユーザー別(病院、外来手術センター、診断センター、クリニック、その他)
    • 企業別(2023年)
    • 地域別
  • 市場マップ

第6章 北米の経口ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 剤形別
    • タイプ別
    • 治療領域別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の経口ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 剤形別
    • タイプ別
    • 治療領域別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋の経口ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 剤形別
    • タイプ別
    • 治療領域別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の経口ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 剤形別
    • タイプ別
    • 治療領域別
    • エンドユーザー別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの経口ドラッグデリバリー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 剤形別
    • タイプ別
    • 治療領域別
    • エンドユーザー別
    • 国別
  • MEA:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併買収(もしあれば)
  • 製品上市(もしあれば)
  • 最近の動向

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Novartis AG
  • Biocon Ltd.
  • NovoNordisk A/S
  • F.Hoffmann-La Roche Ltd.
  • Bayer AG
  • Emishphere Technologies Inc.
  • Enteris Biopharma Inc.
  • Merrion Pharmaceuticals Plc.
  • Amgen Inc.
  • Pfizer Inc.

第15章 戦略的提言

第16章 免責事項

目次
Product Code: 7236

Global Oral Drug Delivery Market was valued at USD 120.44 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.74% through 2029.The Oral Drug Delivery Market encompasses the sector within the pharmaceutical industry dedicated to the development, manufacturing, and commercialization of medications administered via the oral route. This market segment is of paramount importance as oral drug delivery is one of the most common and preferred methods for medication administration due to its convenience, ease of use, and patient compliance. Oral drug delivery systems encompass a wide range of formulations, including tablets, capsules, liquids, and orally disintegrating tablets, among others. Within this market, pharmaceutical companies invest heavily in research and development to innovate new drug delivery technologies aimed at enhancing drug efficacy, bioavailability, and patient outcomes.

Key Market Drivers

Rising Prevalence of Chronic Diseases

The escalating prevalence of chronic diseases worldwide, comprising ailments such as cardiovascular diseases, diabetes, and cancer, stands as a formidable driver propelling the growth trajectory of the Global Oral Drug Delivery Market. This surge in chronic conditions poses a significant healthcare challenge, necessitating effective management and treatment strategies. As the burden of chronic diseases continues to mount, there emerges an ever-growing demand for oral medications that provide not only therapeutic efficacy but also convenience and long-term management options for patients. Oral drug delivery systems offer a crucial solution by providing a non-invasive and easily administrable route for medication intake. This convenience factor plays a pivotal role in enhancing patient adherence to prescribed treatment regimens, a critical aspect in achieving optimal therapeutic outcomes. By simplifying the medication process and minimizing discomfort associated with other routes of drug administration, oral drug delivery systems effectively empower patients to adhere to their treatment plans diligently. Consequently, this enhanced patient compliance not only fosters better disease management but also drives the sustained growth and expansion of the Global Oral Drug Delivery Market, as pharmaceutical companies continue to invest in innovative formulations and technologies to meet the evolving needs of patients worldwide.

Technological Innovations in Drug Delivery Platforms

Technological innovations in drug delivery platforms are playing a pivotal role in shaping the evolution of the Global Oral Drug Delivery Market. With relentless advancements, novel delivery systems such as oral films, implants, and buccal patches have emerged as frontrunners, offering a paradigm shift in drug administration strategies. These cutting-edge technologies not only facilitate traditional drug delivery but also offer distinctive advantages such as targeted delivery, controlled release, and site-specific action, thus revolutionizing the treatment landscape.

Oral films, for instance, represent a groundbreaking innovation in drug delivery, providing a thin, flexible, and dissolvable platform for drug administration. These films can be conveniently placed on the tongue or inside the cheek, facilitating rapid drug absorption and bypassing the digestive system for enhanced bioavailability. Similarly, implants offer a sustained-release mechanism, releasing medication gradually over an extended period, thereby reducing dosing frequency and enhancing patient compliance. Additionally, buccal patches provide localized delivery of drugs through the mucous membrane of the cheek, enabling targeted therapy and minimizing systemic side effects.

Expanding Pharmaceutical Industry Investments

The Global Oral Drug Delivery Market derives substantial benefits from the considerable investments poured into research, development, and commercialization of oral drug delivery technologies by pharmaceutical companies. These investments serve as catalysts propelling innovation within the market, fostering the rapid introduction of novel oral formulations, and nurturing collaborative endeavors among industry stakeholders, thus fueling overall market growth.

Pharmaceutical companies' robust investments in research and development represent a cornerstone of progress within the Global Oral Drug Delivery Market. These investments fuel the exploration of cutting-edge technologies, formulation techniques, and delivery systems aimed at enhancing drug efficacy, improving patient compliance, and mitigating adverse effects. By allocating resources towards innovative research initiatives, pharmaceutical firms drive the development of next-generation oral drug delivery technologies, thereby expanding the market's scope and potential.Moreover, the commercialization of oral drug delivery technologies is accelerated by substantial investments from pharmaceutical companies. These investments fund pivotal clinical trials, regulatory approvals, and market launches, facilitating the swift transition of promising drug delivery innovations from laboratory to pharmacy shelves. As pharmaceutical companies commit significant financial resources to commercialization efforts, they expedite the availability of new oral formulations to healthcare providers and patients worldwide, thereby stimulating market growth.

Government Initiatives to Improve Healthcare Access

Government initiatives aimed at enhancing healthcare access and affordability play a pivotal role in bolstering the growth of the global oral drug delivery market. These initiatives encompass a spectrum of policies and programs geared towards fostering an environment conducive to market expansion, driving demand for oral medications, and promoting improved patient outcomes.

One significant aspect of government initiatives is the promotion of generic drug utilization through policies aimed at increasing affordability and accessibility of medications. By encouraging the use of generic equivalents of branded drugs, governments can lower healthcare costs for patients and healthcare systems alike, thereby expanding access to oral medications. This increased accessibility fosters market growth by broadening the patient base and driving demand for oral drug delivery products.

Government interventions in drug pricing regulations contribute to the growth of the Global Oral Drug Delivery Market. Price regulations aimed at controlling the cost of pharmaceuticals help ensure affordability for patients and healthcare systems, thereby stimulating demand for oral medications. By implementing policies that balance affordability with pharmaceutical innovation, governments create a stable market environment conducive to sustained growth and expansion.

Key Market Challenges

Bioavailability Enhancement

One of the foremost challenges facing the Global Oral Drug Delivery Market is enhancing the bioavailability of orally administered medications. Many drugs encounter significant degradation and poor absorption in the gastrointestinal tract, leading to reduced efficacy and therapeutic outcomes. Overcoming these barriers requires innovative formulation approaches, such as the use of nanotechnology, lipid-based formulations, and novel excipients, to improve drug solubility, permeability, and stability. Additionally, optimizing drug release profiles and absorption kinetics through controlled-release formulations and drug delivery systems represents a critical area of focus for pharmaceutical companies seeking to maximize the therapeutic potential of oral medications.

Regulatory Compliance and Intellectual Property Protection

Regulatory compliance and intellectual property protection present significant challenges for companies operating in the Global Oral Drug Delivery Market. Developing innovative oral drug delivery technologies necessitates navigating complex regulatory frameworks to ensure compliance with safety, efficacy, and quality standards set forth by regulatory authorities worldwide. Additionally, protecting intellectual property rights is essential for safeguarding investments in research and development and maintaining a competitive edge in the market. Effective strategies for navigating regulatory requirements and securing intellectual property rights are essential for sustaining innovation and driving growth in the Global Oral Drug Delivery Market.

Key Market Trends

Personalized Medicine and Customized Formulations

One notable trend shaping the Global Oral Drug Delivery Market is the shift towards personalized medicine and customized formulations. As advancements in biotechnology and pharmacogenomics continue to unfold, there is an increasing recognition of the importance of tailoring drug therapies to individual patient characteristics such as genetic makeup, disease profile, and lifestyle factors. This trend is driving the development of innovative oral drug delivery systems capable of delivering precise dosages and formulations tailored to meet the unique needs of each patient. Pharmaceutical companies are investing in technologies such as 3D printing and nanotechnology to enable the production of personalized oral drug formulations, thereby enhancing treatment efficacy and patient outcomes.

Integration of Digital Health Technologies

Another significant trend in the Global Oral Drug Delivery Market is the integration of digital health technologies into oral drug delivery systems. With the proliferation of smartphones, wearables, and connected devices, there is a growing opportunity to enhance medication adherence, monitoring, and patient engagement through digital solutions. Pharmaceutical companies are increasingly incorporating features such as smart pill bottles, medication reminder apps, and real-time tracking sensors into oral drug delivery devices to empower patients and healthcare providers with actionable insights into medication adherence and treatment response. This trend not only improves patient outcomes but also facilitates data-driven decision-making and clinical research in the field of oral drug delivery.

Segmental Insights

Formulation Insights

Based on the Formulation, in the global Oral Drug Delivery Market, tablets stand out as the dominant formulation method. Tablets have secured their prominence due to several compelling factors. Tablets offer unparalleled convenience and ease of administration, making them a preferred choice for patients across diverse demographics. Their solid form allows for convenient storage, transport, and dosing accuracy, enhancing patient compliance and medication adherence.

Additionally, tablets facilitate precise dosing and formulation control, enabling pharmaceutical companies to deliver a wide range of active pharmaceutical ingredients (APIs) in a stable and reproducible manner. Furthermore, tablets can be manufactured using a variety of technologies, including immediate-release, modified-release, and extended-release formulations, catering to diverse therapeutic needs and patient preferences. Moreover, tablets often undergo rigorous quality control measures and stability testing, ensuring their efficacy, safety, and shelf-life. Overall, tablets' versatility, convenience, and reliability position them as the dominant formulation method in the global Oral Drug Delivery Market, driving their widespread adoption and market dominance.

Type Insights

Based on the Type segment, the Controlled Release type stands out as the dominant type among the various categories. This dominance can be attributed to several key factors. Controlled release formulations offer significant advantages over conventional immediate-release formulations by providing sustained and controlled drug release over an extended period. This allows for less frequent dosing, improved patient compliance, and enhanced therapeutic efficacy.

As a result, pharmaceutical companies are increasingly investing in the development of controlled release oral drug delivery systems across a wide range of therapeutic areas, including chronic diseases such as diabetes, hypertension, and pain management. Moreover, advancements in drug delivery technologies, such as matrix systems, osmotic pumps, and microencapsulation techniques, have enabled the precise modulation of drug release kinetics, further enhancing the therapeutic benefits of controlled release formulations.

Additionally, the growing prevalence of chronic diseases worldwide, coupled with an aging population and increasing healthcare expenditure, drives the demand for long-acting oral medications that offer sustained symptom relief and improved disease management. Consequently, the controlled release segment continues to dominate the global Oral Drug Delivery Market, offering significant growth opportunities for pharmaceutical companies and driving advancements in drug delivery science and technology.

Regional Insights

North America emerges as the dominant region in the Global Oral Drug Delivery Market. Several factors contribute to its prominence in this market segment. North America boasts a robust pharmaceutical industry with a high level of research and development investment, leading to continuous innovation in oral drug delivery technologies. The region benefits from advanced healthcare infrastructure and a well-established regulatory framework that facilitates the development, approval, and commercialization of oral drug delivery products.

A significant portion of pharmaceutical companies specializing in oral drug delivery systems are headquartered in North America, further bolstering its leadership position. Moreover, the region has a large patient population with a high prevalence of chronic diseases, driving the demand for oral medications and propelling market growth. Favorable reimbursement policies and strong market competition contribute to the dynamic and thriving nature of the oral drug delivery market in North America.

Key Market Players

Novartis AG

Biocon Ltd.

NovoNordisk A/S

F.Hoffmann-La Roche Ltd.

Bayer AG

Emishphere Technologies Inc.

Enteris Biopharma Inc.

Merrion Pharmaceuticals Plc.

Amgen Inc.

Pfizer Inc.

Report Scope:

In this report, the Global Oral Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Drug Delivery Market, By Formulation:

  • Tablets
  • Capsules
  • Drops
  • Liquid or Syrup

Oral Drug Delivery Market, By Type:

  • Controlled Release
  • Orodispersible Tablets
  • Others

Oral Drug Delivery Market, By Therapy Area:

  • Oncology
  • Musculoskeletal
  • Immunology
  • Gastrointestinal
  • Respiratory
  • Cardiovascular
  • Others

Oral Drug Delivery Market, By End User:

  • Hospitals
  • Ambulatory Surgical Centres
  • Diagnostic Centres
  • Clinics
  • Others

Oral Drug Delivery Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oral Drug Delivery Market.

Available Customizations:

Global Oral Drug Delivery market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market

4.Voice of Customer

5.Global Oral Drug Delivery Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
    • 5.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
    • 5.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
    • 5.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
    • 5.2.5.By Company (2023)
    • 5.2.6.By Region
  • 5.3.Market Map

6.North America Oral Drug Delivery Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
    • 6.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
    • 6.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
    • 6.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
    • 6.2.5.By Country
  • 6.3.North America: Country Analysis
    • 6.3.1.United States Oral Drug Delivery Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Formulation
        • 6.3.1.2.2.By Type
        • 6.3.1.2.3.By Therapy Area
        • 6.3.1.2.4.By End User
    • 6.3.2.Canada Oral Drug Delivery Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Formulation
        • 6.3.2.2.2.By Type
        • 6.3.2.2.3.By Therapy Area
        • 6.3.2.2.4.By End User
    • 6.3.3.Mexico Oral Drug Delivery Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Formulation
        • 6.3.3.2.2.By Type
        • 6.3.3.2.3.By Therapy Area
        • 6.3.3.2.4.By End User

7.Europe Oral Drug Delivery Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
    • 7.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
    • 7.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
    • 7.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
    • 7.2.5.By Country
  • 7.3.Europe: Country Analysis
    • 7.3.1.France Oral Drug Delivery Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Formulation
        • 7.3.1.2.2.By Type
        • 7.3.1.2.3.By Therapy Area
        • 7.3.1.2.4.By End User
    • 7.3.2.Germany Oral Drug Delivery Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Formulation
        • 7.3.2.2.2.By Type
        • 7.3.2.2.3.By Therapy Area
        • 7.3.2.2.4.By End User
    • 7.3.3.United Kingdom Oral Drug Delivery Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Formulation
        • 7.3.3.2.2.By Type
        • 7.3.3.2.3.By Therapy Area
        • 7.3.3.2.4.By End User
    • 7.3.4.Italy Oral Drug Delivery Market Outlook
      • 7.3.4.1.Market Size Forecast
        • 7.3.4.1.1.By Value
      • 7.3.4.2.Market Share Forecast
        • 7.3.4.2.1.By Formulation
        • 7.3.4.2.2.By Type
        • 7.3.4.2.3.By Therapy Area
        • 7.3.4.2.4.By End User
    • 7.3.5.Spain Oral Drug Delivery Market Outlook
      • 7.3.5.1.Market Size Forecast
        • 7.3.5.1.1.By Value
      • 7.3.5.2.Market Share Forecast
        • 7.3.5.2.1.By Formulation
        • 7.3.5.2.2.By Type
        • 7.3.5.2.3.By Therapy Area
        • 7.3.5.2.4.By End User

8.Asia-Pacific Oral Drug Delivery Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
    • 8.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
    • 8.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
    • 8.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
    • 8.2.5.By Country
  • 8.3.Asia-Pacific: Country Analysis
    • 8.3.1.China Oral Drug Delivery Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Formulation
        • 8.3.1.2.2.By Type
        • 8.3.1.2.3.By Therapy Area
        • 8.3.1.2.4.By End User
    • 8.3.2.India Oral Drug Delivery Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Formulation
        • 8.3.2.2.2.By Type
        • 8.3.2.2.3.By Therapy Area
        • 8.3.2.2.4.By End User
    • 8.3.3.Japan Oral Drug Delivery Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Formulation
        • 8.3.3.2.2.By Type
        • 8.3.3.2.3.By Therapy Area
        • 8.3.3.2.4.By End User
    • 8.3.4.South Korea Oral Drug Delivery Market Outlook
      • 8.3.4.1.Market Size Forecast
        • 8.3.4.1.1.By Value
      • 8.3.4.2.Market Share Forecast
        • 8.3.4.2.1.By Formulation
        • 8.3.4.2.2.By Type
        • 8.3.4.2.3.By Therapy Area
        • 8.3.4.2.4.By End User
    • 8.3.5.Australia Oral Drug Delivery Market Outlook
      • 8.3.5.1.Market Size Forecast
        • 8.3.5.1.1.By Value
      • 8.3.5.2.Market Share Forecast
        • 8.3.5.2.1.By Formulation
        • 8.3.5.2.2.By Type
        • 8.3.5.2.3.By Therapy Area
        • 8.3.5.2.4.By End User

9.South America Oral Drug Delivery Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
    • 9.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
    • 9.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
    • 9.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
    • 9.2.5.By Country
  • 9.3.South America: Country Analysis
    • 9.3.1.Brazil Oral Drug Delivery Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Formulation
        • 9.3.1.2.2.By Type
        • 9.3.1.2.3.By Therapy Area
        • 9.3.1.2.4.By End User
    • 9.3.2.Argentina Oral Drug Delivery Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Formulation
        • 9.3.2.2.2.By Type
        • 9.3.2.2.3.By Therapy Area
        • 9.3.2.2.4.By End User
    • 9.3.3.Colombia Oral Drug Delivery Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Formulation
        • 9.3.3.2.2.By Type
        • 9.3.3.2.3.By Therapy Area
        • 9.3.3.2.4.By End User

10.Middle East and Africa Oral Drug Delivery Market Outlook

  • 10.1.Market Size Forecast
    • 10.1.1.By Value
  • 10.2.Market Share Forecast
    • 10.2.1.By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
    • 10.2.2.By Type (Controlled Release, Orodispersible Tablets, Others)
    • 10.2.3.By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
    • 10.2.4.By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
    • 10.2.5.By Country
  • 10.3.MEA: Country Analysis
    • 10.3.1.South Africa Oral Drug Delivery Market Outlook
      • 10.3.1.1.Market Size Forecast
        • 10.3.1.1.1.By Value
      • 10.3.1.2.Market Share Forecast
        • 10.3.1.2.1.By Formulation
        • 10.3.1.2.2.By Type
        • 10.3.1.2.3.By Therapy Area
        • 10.3.1.2.4.By End User
    • 10.3.2.Saudi Arabia Oral Drug Delivery Market Outlook
      • 10.3.2.1.Market Size Forecast
        • 10.3.2.1.1.By Value
      • 10.3.2.2.Market Share Forecast
        • 10.3.2.2.1.By Formulation
        • 10.3.2.2.2.By Type
        • 10.3.2.2.3.By Therapy Area
        • 10.3.2.2.4.By End User
    • 10.3.3.UAE Oral Drug Delivery Market Outlook
      • 10.3.3.1.Market Size Forecast
        • 10.3.3.1.1.By Value
      • 10.3.3.2.Market Share Forecast
        • 10.3.3.2.1.By Formulation
        • 10.3.3.2.2.By Type
        • 10.3.3.2.3.By Therapy Area
        • 10.3.3.2.4.By End User

11.Market Dynamics

  • 11.1.Drivers
  • 11.2.Challenges

12.Market Trends Developments

  • 12.1.Merger Acquisition (If Any)
  • 12.2.Product Launches (If Any)
  • 12.3.Recent Developments

13.Porters Five Forces Analysis

  • 13.1.Competition in the Industry
  • 13.2.Potential of New Entrants
  • 13.3.Power of Suppliers
  • 13.4.Power of Customers
  • 13.5.Threat of Substitute Products

14.Competitive Landscape

  • 14.1.Novartis AG
    • 14.1.1.Business Overview
    • 14.1.2.Company Snapshot
    • 14.1.3.Products Services
    • 14.1.4.Financials (As Reported)
    • 14.1.5.Recent Developments
    • 14.1.6.Key Personnel Details
    • 14.1.7.SWOT Analysis
  • 14.2.Biocon Ltd.
  • 14.3.NovoNordisk A/S
  • 14.4.F.Hoffmann-La Roche Ltd.
  • 14.5.Bayer AG
  • 14.6.Emishphere Technologies Inc.
  • 14.7.Enteris Biopharma Inc.
  • 14.8.Merrion Pharmaceuticals Plc.
  • 14.9.Amgen Inc.
  • 14.10.Pfizer Inc.

15.Strategic Recommendations

16.About Us Disclaimer